Economic evaluation, in Italy, of therapies for advanced Parkinson's disease;Analisi dei costi, in Italia, di diverse strategie per il trattamento della malattia di Parkinson in fase avanzata

Recenti Progressi in Medicina

Volumn 94, Issue 11, 2003, Pages 484-493

  D'Ausilio, Anna ^a   Marconi, Stefano ^b   Antonini, Angelo ^c   Tamma, Filippo ^d   Valzania, Franco ^e   Berto, Patrizia ^a  

^a Pbe Consulting   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c Istituti Clinici di Perfezionamento   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

^e BELLARIA HOSPITAL   (Italy)

Author keywords

Advanced Parkinson's disease; Deep brain stimulation; L dopa drugs; Subcutaneous apomorphine

Indexed keywords

APOMORPHINE; LEVODOPA;

BRAIN DEPTH STIMULATION; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; ELECTRODE; HEALTH CARE; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; ITALY; MEDICAL LITERATURE; NERVE STIMULATION; PARKINSON DISEASE; REDUCTION; REVIEW; TRADITIONAL MEDICINE;

ANTIPARKINSON AGENTS; APOMORPHINE; COSTS AND COST ANALYSIS; DOPAMINE AGONISTS; DRUG COSTS; ELECTRIC STIMULATION THERAPY; HEALTH RESOURCES; HEALTH SURVEYS; HOSPITAL COSTS; HUMANS; INFUSION PUMPS; INSURANCE, HEALTH, REIMBURSEMENT; ITALY; LEVODOPA; NATIONAL HEALTH PROGRAMS; OUTPATIENT CLINICS, HOSPITAL; PARKINSON DISEASE;

EID: 0344010028     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Dodel, et al. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease. Pharmacoeconomics 2001; 19: 1013-38.
2. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity. Pharmacoeconomics 1997; 12: 486-98.
3. Hagell P, et al. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs 2001; 33: 21-34; 37-8.
4. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000; 15: 789-94.
5. LIMPE, Linee Guida per il trattamento della malattia di Parkinson. Neurological Sciences 2000; 21 (suppl).
6. Stocchi F, et al. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997; 20: 95-115.
7. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psych 1998; 64: 573-6.
8. Stocchi F, Vacca L, De Pandis MF. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001; 22: 93-4.
9. Pollak P, et al. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 1990; 146: 116-22.
10. Grandas F, Gancher ST, et al. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1992; 15: 13-8.
11. Olanow CW. The role of deep brain stimulation as a surgical treatment for Parkinson's disease. Neurology 2000; 55(suppl 6): S60-6.
12. Diederich NJ, et al. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol 2000; 23: 287-9.
13. Fields JA, Troster AI. Cognitive outcomes after deep brain stimulation for Parkinson's disease: a review of initial studies and recommendations for future research. Brain Cogn 2000; 42: 268-93.
14. Gerzeli S, Cavallo MC, Ponzi P. Gruppo di Studio DBS. Analisi dei costi della stimolazione cerebrale profonda (DBS) nella malattia di Parkinson: uno studio osservazionale su pazienti italiani, Pharmacoeconomics 2002; 4: 65-79.
15. Drummond MF, O'Brien B, Stoddard GL, Torrance GW. Methods for the economic evaluation of health-care programmes. Oxford: Oxford University Press 1997.
16. Ministero della Sanità. Nomenclatore tariffario. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del SSN e relative tariffe. DM 22 Luglio 1996.
17. Mistero della Sanità. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera di cui al DM 14 dicembre 19994; DM 30 giugno 1997, SO G.U. n. 209, 8 settembre 1997.
18. Ministero della Salute. Database Farmaci (www.sanita.it: accesso del 5 settembre).
19. Marchese E, Vichi MC. Un utilizzo del percorso del paziente: la valorizzazione economica del trattamento chirurgico della malattia di Parkinson. Mecosan 2000; 36: 55-78.
20. Pollak P, Benebid AL, Limousin P, et al. External and implanted pumps for apomorphine infusion in Parkinsonism. Acta Neurochir 1993; 58 (suppl): 48-52.
21. Stocchi F, Bramante L, Monge A, et al. Apomorphine and Lisuride infusion. A comparative chronic study. Adv in Neurol 1993; 60: 653-55.
22. Colosimo C, Albanese A, Cassetta E, et al. Subcutaneous apomorphine in Parkinson's disease. Mov Disorders 1994; 9: 265.
23. Ruggirei S, Nordera G, Stocchi F, et al. Studio multicentrico, prospettico, non controllato per la valutazione di efficacia e tollerabilità di apomorfina fiale somministrate sottocute mediante pompa infusiva in pazienti affetti da m. di Parkinson caratterizzato da severi blocchi motori pluriquotidiani. Rapporto non pubblicato 1996.
24. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's Disease. J Neurol Neurosurg Psych 1990; 53: 96-101.
25. Stibe CMH, Kempster PA, Lees JA, Stern GM. Subcutaneous apomorphine in Parkinsonian on-off oscillation. Lancet 1988; 1: 403-6.
26. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Dis 1995; 10: 37-43.
27. Pollak P, Champay AS, Hommel M, et al. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psych 1989; 52: 544.
28. Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson's disease. J Neurol 1992; 239: 389-93.
29. Colzi A, Turner K, Lees AJ. Continuous walking-day subcutaneous apomorphine therapy in the treatment of L-dopa-induced dyskinesias and "off-on" phenomena in Parkinson's Disease. 12th Int Symp on Parkinson's Disease. London: March 23-26, 1997, Abstr P428.
30. Pollak P, Champay AS, Gaio JM, Hommel M, et al. Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladie de Parkinson, Rev Neurol (Paris) 1990; 146: 116-22.